| Cancer is heterogeneous disease may develop by interplay of alterations in multiple genes which play an important role in cell growth, differentiation and cell death. Sequencing of single genes does not provide complete knowledge of pathways that are affected and often, relevant information is not available. The prognosis & treatment decisions may depend on multiple gene mutations. |
TumorTrack Advance
What is TumorTrack Advance Test?
TumorTrack Advance is a next generation sequencing (NGS) assay consisting of DNA and RNA based testing which detects single nucleotide variants (SNVs), small insertion-deletion mutations (InDels), copy number variants (CNVs), fusions, tumor mutation burden (TMB), microsatellite instability (MSI) and Homologous Recombination Deficiency (HRD) in multiple solid tumors.
Key Biomarkers Covered
| Test Name | Details | |
|---|---|---|
| Breast Cancer | ||
| Ovarian Cancer | ||
| Endometrial Cancer | ||
| Colon Cancer | ||
| Pancreatic Cancer | ||
| Prostate Cancer | ||
| Lung Cancer | ||
| Pan-Cancer |
Clinical Applications of TumorTrack Advance
- Single holistic test for the diagnosis, prognosis and to determine treatment options (Targeted Therapy & Immunotherapy).
- To identify potential targeted therapies in a newly diagnosed cancer patient.
- To determine the diagnosis and prognosis of the disease.
- To detect drug resistance and plan on change of treatment regimen.
- Determining the next course of action in patients that have progressed on first / second line treatment.
- Designing treatment strategies in patients with unknown primary cancer.
- Selection of patients for clinical trials.
Specifications
- Indications: All Solid tumor Types.
- Methodology: Next Generation Sequencing.
- Sample Type: FFPE Tissue Block, Cytology Cell Block, Tissue in RNA later.
- Accuracy: Analytical Sensitivity: 100% (SNVs/InDels); 98% Fusions; ≥85-90% (CNVs) I Analytical Specificity >99.9% I Average Depth of sequencing: >250X I Limit of detection: 3 - 5% VAF for SNV and InDels, >10 Spanning Reads for Fusions.
- Coverage: SNVs, CNVs, InDels, Fusions, TMB, MSI and HRD.
Tissue Biopsy Based Tests Offered by MedGenome
TumorTrack Advance - Comprehensive Tumor Panel
-
Detects: >500 genes SNVs, Indels, CNVs, Fusions, TMB, MSI and HRD
-
TAT: 21 working days
-
Test Code: MGM1785
TumorTrack - Comprehensive Tumor Pane
-
Detects: ~400 genes SNVs, Indels, CNVs, Fusions and TMB
-
TAT: 21 working days
-
Test Code: MGM1879
TumorFocus panel by NGS
-
Detects: 77 genes SNVs, Indels, CNVs and Fusions
-
TAT: 14 working days
-
Test Code: MGM3446
Tumor Mutation panel (SNVs, InDels & CNVs)
-
Detects: 231 genes SNVs, Indels, CNVs
-
TAT: 14 working days
-
Test Code: MGM196
Tumor Mutation Burden (TMB) analysis by NGS
-
Detects: TMB
-
TAT: 14 working days
-
Test Code: MGM1556
Key Advantages of MedGenome's TumorTrack Advance
Genes Recommended
All genes recommended by guidelines (FDA, NCCN, ASCO, ESMO) across tumor types are covered.
Comprehensive coverage
Complete coding regions of all the genes and intron/exon boundaries.
CAP guidelines
Well validated as per CAP guidelines; >98% sensitivity and specificity with 100% accuracy and precision using orthogonal assays/reference standards.
Get Genetic Counselling by Our Experts
Connect with Our Experts
MedGenome Patient Stories
MedGenome in the News
Please share your details to get
in touch with our experts.
